Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow SRPT by emailGet an email when SRPT pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SRPT, unsubscribe in one click. Privacy
📣 What SRPT Says Is Next
by year-end 2026 · “For ELEVIDYS, full enrollment of ENDEAVOR Cohort 8 expected by year-end 2026 and 12-week data from the full cohort in Q1 2027.”
Company press release, Aug 5, 2026 · SEC filing
2H 2026 · “Key 2H 2026 milestones update: Readouts from our MAD cohorts of our ongoing phase 1/2 studies in DM1 and FSHD remain on track for 2H 2026.”
Company press release, Aug 5, 2026 · SEC filing
fourth quarter · “Sarepta will report its final and complete fourth quarter and full-year 2025 financial results in late February 2026.”
Company press release, Jan 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full SRPT picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SRPT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.